US EditionPublished • loading... • Updated
Gsk Merger with Astrazeneca After Appointment of New Ceo?
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Abhishek Raval, an analyst in the pharmaceutical sector at AlphaValue wonders whether the designation of GSK’s new CEO (CEO) cannot facilitate the merger of the two companies: GSK and AstraZeneca. In a note to customers, Raval reasons this possibility and raises the target price of GSK to 2,186 pence from the previous 2,086 pence, up 4.79%, while reiterating his recommendation of Add. Raval points out in his note entitled “Preparing to face the …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
